EMA Authorised: Bemfola (follitropin alfa) — Gedeon Richter Plc.

View source ↗

Summary

The EMA authorised Bemfola (follitropin alfa) with Gedeon Richter Plc. as the marketing authorization holder. The therapeutic area listed is anovulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anovulation

Drugs mentioned

• Bemfola (follitropin alfa)

Snippet

Status: Authorised. Therapeutic area: Anovulation. MAH: Gedeon Richter Plc.. Decision date: 23/03/2026